Key takeaways for Rhode Island
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • RIte Care coverage rules apply for Prediabetes patients in Rhode Island — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Rhode Island-specific context
Rhode Island has telehealth access concentrated in Providence, Warwick, Cranston metros, with additional reach to Pawtucket and East Providence. Lifespan, Care New England is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.ri.gov.
Rhode Islandtelehealth & pricing rules
- • Rhode Island requires a live video consultation before a GLP-1 prescription.
- • Rhode Island allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Rhode Island: ~$322/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.